Industry Outlook
The dilated cardiomyopathy therapeutics market is set to reach US$ xx Mn by 2026 from US$ xx Mn in 2017 featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.7% during the forecast period from 2018 to 2026. As per the latest research citings of World Health Organization (WHO), annually 17.9 million people die throughout the globe from cardiovascular diseases which is equivalent o 31% of all global deaths. Factors responsible for congestive heart failure are sedentary lifestyle, obesity, unhealthy lifestyle and congenital heart complications.
Pharmaceuticals companies are striving earnestly to manufacture drugs with least possible side effects and desired therapeutic efficacy. Drugs in Phase III clinical trials showing promising results are enalapril orodispersible minitablets (Ethicare GmbH), ARRY-371797 (Array BioPharma) and ixCELL-DCM (Vericel Corporation).
Market Synopsis
Excellent clinical outcomes and satisfactory patient compliance makes drug class the most viable treatment option for dilated cardiomyopathy
In the current scenario drug class are reigning the treatment segment for dilated cardiomyopathy therapeutics market. The parameters responsible for the growth of drug class are increasing number of patients diagnosed with congestive heart failure. Moreover excellent clinical outcomes and satisfactory patient compliance make drug class the most viable option for the treatment of dilated cardiomyopathy. Angiotensin converting enzyme inhibitors (ACE inhibitors) are considered as first line of drug therapy due to its positive clinical effects such as relaxing heart muscles and promoting blood flow. Angiotensin receptor blockers are given with diuretics to patients that do not tolerate ACE inhibitors. They help to regulate the blood flow by widening of blood vessels and reducing the fluid in lungs and kidneys. Beta blockers and anticoagulants are prescribed to reduce the pressure on the heart valves and prevent blood clotting in the heart chambers due to inability of the weakened left ventricular muscles to pump the blood. Implantable devices are gaining traction owing to the side effects associated with drug class and long term benefit provided by devices such as heart pumps, biventricular pacemakers and implantable cardioveter-defibrillators.
Rising prevalence of congestive heart failure drive the dilated cardiomyopathy therapeutics market growth in North America
North America is currently leading the geography segment for dilated cardiomyopathy therapeutics market owing to factors such as rising prevalence of congestive heart failure. According to the facts presented by Center for Disease Control and Prevention (CDC) in United States approximately 610,000 people die of heart disease annually. Existence of well-developed healthcare infrastructure and affordable reimbursement scenario drive the dilated cardiomyopathy market growth in North America. As per the latest research citings of European Heart Network (EHN) every year 3.9 million people die in Europe amounting to 45% of all deaths caused in the region. Domicile of major players such as Merck & Co., Inc., GlaxoSmithKline Plc and t2cure GmbH etc., propel the market growth in European Union region. Asia Pacific will register outstanding growth during the forecast period on account of rising prevalence of congenital heart diseases, favorable regulatory scenario and growing medical tourism due to affordable treatment cost. Latin America and Middle East & Africa serve as a potential market to promote business expansion opportunities by establishing subsidiaries and retail outlets for major players proving treatment option for dilated cardiomyopathy.
Historical & Forecast Period
2016 – Historical Year
2017 – Base Year
2018-2026 – Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
Market estimation and compounded annual growth rate were determined by studying the latest market trends prevalent in dilated cardiomyopathy therapeutics market. The market is subsegmented as by treatment and regional segment.
By Treatment (2016–2026; US$ Mn)
Geography Segment (2016–2026; US$ Mn)
Pharmaceutical companies spearheading the dilated cardiomyopathy therapeutics market are Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithkline Plc, Johnson and Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure, GmbH, Teva Pharmaceutical Industries, ZensunSci & Tech.
Key questions answered in this report
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global Dilated Cardiomyopathy Therapeutics Market Portraiture
2.2. Global Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2017 (US$ Mn)
2.3. Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2017 (US$ Mn)
Chapter 3. Dilated Cardiomyopathy Therapeutics Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Key Players, 2017
Chapter 4. Global Dilated Cardiomyopathy Therapeutics Market, by Treatment
4.1. Overview
4.2. Drug Class
4.2.1. Angiotensin II Receptor Blockers
4.2.2. Angiotensin-Converting Enzyme (ACE) Inhibitors
4.2.3. Beta Blockers
4.2.4. Anticoagulants
4.2.5. Digitalis
4.2.6. Diuretics
4.3. Implantable Device
4.3.1. Heart Pumps
4.3.2. Biventricular Pacemakers
4.3.3. Implantable Cardioverter-Defibrillators
4.4. Pipeline Analysis
4.4.1. Phase III Drugs
4.4.1.1. Enalapril Orodispersible Minitablet
4.4.1.2. ARRY-371797
4.4.1.3. ixCELL-DCM
4.4.2. Tabular Representation of Drug Pipeline in Phase II and I
Chapter 5. Global Dilated Cardiomyopathy Therapeutics Market, by Geography
5.1. Overview
5.2. North America Dilated Cardiomyopathy Therapeutics Market Analysis, 2016 – 2026
5.2.1. North America Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
5.2.2. North America Dilated Cardiomyopathy Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Dilated Cardiomyopathy Therapeutics Market Analysis, 2016 – 2026
5.3.1. Europe Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
5.3.2. Europe Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Analysis, 2016 – 2026
5.4.1. Asia Pacific Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Dilated Cardiomyopathy Therapeutics Market Analysis, 2016 – 2026
5.5.1. Latin America Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East and Africa Dilated Cardiomyopathy Therapeutics Market Analysis, 2016 – 2026
5.6.1. MEA Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
5.6.2. MEA Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Aastrom Biosciences
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Treatment Portfolio
6.1.4. News Coverage
6.2. Capricor Therapeutics
6.3. GlaxoSmithKline plc.
6.4. Johnson and Johnson
6.5. Kasiak Research Pvt. Ltd.
6.6. Merck & Co., Inc.
6.7. MyoKardia
6.8. Pfizer Inc.
6.9. t2cure GmbH.
6.10. Teva Pharmaceutical Industries
6.11. ZensunSci & tech.
FIG. 1 Dilated Cardiomyopathy Therapeutics Market: Research Methodology
FIG. 2 Dilated Cardiomyopathy Therapeutics: Market Segmentation
FIG. 3 Global Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2017 (US$ Mn)
FIG. 4 Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Key Players, 2017
FIG. 7 Global Angiotensin II Receptor Blockers Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 8 Global ACE Inhibitors Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 9 Global Beta Blockers Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 10 Global Anticoagulants Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 11 Global Digitalis Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 12 Global Diuretics Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 13 Global Heart Pumps Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 14 Global Biventricular Pacemakers Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 15 Global Implantable Cardioverter-Defibrillators Market for Dilated Cardiomyopathy Therapeutics, 2016 – 2026 (US$ Mn)
FIG. 16 U.S. Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 17 Canada Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 18 U.K. Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 19 Germany Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 20 Rest of Europe Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 21 China Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 22 Japan Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 23 Rest of Asia Pacific Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 24 Brazil Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 25 Mexico Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 26 Rest of Latin America Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 27 GCC Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 28 Rest of MEA Dilated Cardiomyopathy Therapeutics Market, 2016 – 2026 (US$ Mn)
TABLE 1 Global Dilated Cardiomyopathy Therapeutics Market Portraiture
TABLE 2 Global Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 3 Global Drug Class Market for Dilated Cardiomyopathy Therapeutics, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 4 Global Implantable Device Market for Dilated Cardiomyopathy Therapeutics, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 5 Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 7 North America Dilated Cardiomyopathy Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 15 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Aastrom Biosciences: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 17 Capricor Therapeutics: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 18 GlaxoSmithkline Plc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 19 Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 20 Kasiak Research Pvt. Ltd.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 22 Myokardia: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 23 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 24 T2cure GmbH: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 25 Teva Pharmaceuticals Industries: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 26 ZensunSci & tech.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
